Advertisements

Mutaflor

Quick links to important sections

Mutaflor

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Mutaflor

What is Mutaflor? Defining a Unique Probiotic Medicine

Property Description
Active ingredient Escherichia Coli strain Nissle 1917
Form Enteric-coated capsules (and suspension)
Pharmacological class Probiotic, Gastrointestinal Agent
General purpose Stabilization of intestinal microflora
Origin Biological / Natural

Mutaflor is a specialized microbiological preparation classified as a probiotic and a gastrointestinal agent, distinguished by its single active component, the non-pathogenic bacterial strain, Escherichia Coli strain Nissle 1917. This oral medication is considered a live biotherapeutic product because its function is derived from this living, specific bacterial culture that works within the digestive system. The efficacy and safety of the E. coli Nissle 1917 strain have been documented in clinical research since its isolation, confirming its historical and continued role as a reliable agent in gut health. This research indicates the medicine supports the balance of the gut environment. Mutaflor is often a prescription-only medication in many jurisdictions, underscoring its recognized medical positioning compared to general dietary supplements.

Composition and Pharmaceutical Form of Mutaflor

The active ingredient in Mutaflor is exclusively the viable bacteria Escherichia Coli strain Nissle 1917, making the preparation a monotherapy product. The strain's origin, isolated in 1917 from a soldier who remained free of dysentery during an epidemic, highlights its long-established presence and unique antagonistic properties in medical use. The medicine is primarily supplied as enteric-coated capsules for oral administration. The enteric coating is a critical design feature, ensuring the live bacterial culture is protected from the corrosive acidic environment of the stomach. This protection guarantees that the active ingredient is delivered intact to the lower intestinal tract, where it can colonize and begin its intended action.

General Purpose: Why is Mutaflor Used for the Gut?

The general purpose of Mutaflor is to contribute to the stabilization of the intestinal microflora and support the structural integrity of the gut lining. By introducing and establishing the specific E. coli Nissle 1917 strain, the medicine helps the body maintain a balanced microbial environment through mechanisms like competitive exclusion against undesirable microbes and support of the gut barrier function. This comprehensive action is intended to enhance the overall resilience of the gastrointestinal system, often supporting patients seeking relief from chronic or recurring functional disturbances of the bowel.

Advertisements

What side effects are possible with Mutaflor?

Possible Side Effects and Safety Information

The safety profile for Mutaflor, which contains the live biotherapeutic Escherichia Coli strain Nissle 1917, is based on adverse reactions and classifications documented in official government regulatory information.


Frequency and System-Organ Classification

The officially documented adverse reactions are categorized primarily within the Gastrointestinal, Nervous System, and Skin system-organ classes. The frequency of these effects aligns with regulatory standards:

  • Common Reactions (may affect up to 1 in 10 people): The most frequently reported effect is flatulence (bloating), which is often observed at the beginning of administration and tends to resolve with continued use.
  • Very Rare Reactions (may affect less than 1 in 10,000 people): These include specific Gastrointestinal Disorders (such as abdominal pain, gut noises, loose stools, diarrhea, nausea, and vomiting), Nervous System Disorders (headache), and Skin reactions (rashes or reddening).

Official Safety Restrictions and Considerations

The medicine is formally contraindicated in individuals with a known hypersensitivity (allergy) to E. coli strain Nissle 1917 or any other component of the formulation.

Regulatory documents also detail a specific serious safety consideration related to population risk: the occurrence of sepsis (blood poisoning) has been reported in isolated cases in extremely premature infants (birth weight less than 1000 g). The frequency of this event is classified as Not Known.

Furthermore, the safety profile notes that co-administration of certain antibiotics and sulfonamides may affect the medicine’s efficacy, a key consideration for its use. No adverse effects are generally expected during pregnancy or lactation, as the bacterium is a natural, non-absorbed gut inhabitant.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Mutaflor addresses the subject of taking more than the intended amount by stating that no case of overdose has been reported in clinical experience.

Due to this finding, official labeling does not define a specific toxic dose level, nor does it list any expected clinical manifestations or symptoms associated with a Mutaflor overdose. The physiological systems that would be affected in an overdose scenario are not described in regulatory documents.

Summary of Official Overdose Information

Overdose Component Official Regulatory Statement
Documented Presentations No case of overdose has been reported.
Emergency Response No special measures are necessary.
Immediate Medical Help No explicit statement to seek immediate medical help is provided.

Should an individual take a quantity of Mutaflor that is higher than the recommended dose, the official documentation states that no special measures are necessary. This statement is a direct reflection of the reported safety profile, where the lack of documented cases leads to a conclusion that the risk is extremely low, and no specific emergency treatment is detailed. Users should nonetheless consult with a doctor or health professional if they have concerns or experience any effects after taking a greater amount than prescribed.

Advertisements

Therapeutic Uses of Mutaflor

Mutaflor, which contains the probiotic strain Escherichia coli Nissle 1917 (EcN), is commonly used to help with symptom clusters that may become intense or disruptive. As a medicinal probiotic, it is applied across domains where additional symptomatic support is needed and is relevant for easing symptoms related to inflammatory or irritative states.

The main therapeutic area of use is for symptomatic support during chronic constipation. For this indication, it may assist with maintaining functional stability, which contributes to easing the overall symptom load. Beyond that context, EcN is considered relevant in contexts involving heightened systemic burden. These commonly include scenarios involving chronic constipation, conditions presenting with systemic or localized discomfort, and symptoms that create noticeable physiological strain. It provides supportive relief when symptoms interfere with routine activities, contributing to easing symptoms related to physical discomfort and systemic imbalance.

“Used in situations involving certain distressing symptoms, this support is commonly used when short-term symptomatic assistance is needed.”

Quick Fact: Relevant for: Easing symptoms related to physical discomfort

It generally contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. MUTAFLOR Escherichia coli strain Nissle 1917...
Advertisements

Eligibility and Restrictions for Use

The official regulatory documentation for Mutaflor defines clear population eligibility rules. The absolute contraindication for use is a documented hypersensitivity or allergy to the active substance, Escherichia coli strain Nissle 1917, or any of the product’s excipients.

Eligibility is established across all age groups, but specific authorization depends on the formulation: the capsule form is approved for adults and adolescents from 12 years of age, while the suspension form is intended for infants, toddlers, and younger children.

For physiological status, Mutaflor is permitted during pregnancy and breastfeeding, as official regulatory data confirms there are no known risks when used as instructed.

Use is conditional in certain contexts. Patients with Ulcerative Colitis are only eligible for treatment during the remission phase of the disease. Furthermore, official precautions note that efficacy may be reduced in populations receiving concurrent treatment with certain antibiotics or sulphonamides. Caution is also advised for use in immunocompromised individuals.

Advertisements

What should I know about interactions with other medicines?

This section outlines the officially documented interaction patterns for Mutaflor (Escherichia coli strain Nissle 1917), based on government regulatory prescribing information.

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Antibiotics and Sulphonamides (specifically those effective against Gram-negative bacteria).
Mechanistic basis of interactions Pharmacodynamic Efficacy Reduction. The antimicrobial action of these medicines reduces the viability of the live bacterial active ingredient.
Timing-based interaction rules Mandatory dose separation of 2 to 4 hours is required when co-administering with Gram-negative targeting antibiotics.
Interaction-related restrictions Restriction involves the mandatory timing separation of administration with certain antimicrobials to prevent the documented reduction of Mutaflor efficacy.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation
Interaction severity classification Clinically Significant Efficacy-Reducing Interaction (managed by administration timing).
Interaction-context constraints None documented for pharmacokinetic pathways, such as CYP-mediated or transporter-based interactions, as the product is not systemically absorbed.

Resulting Interaction Structure

Official product information states that certain antibiotics and sulphonamides may reduce Mutaflor activity due to their bactericidal effect on the live strain. This effect is managed by requiring a specific separation of dosing time. The label does not include any statements regarding metabolic or transporter-mediated interactions, formally contraindicated medicinal combinations, or interactions with food, alcohol, or herbal products.

Advertisements

Mechanism of Action

The mechanism of action of Mutaflor, containing the probiotic strain Escherichia coli Nissle 1917 (EcN), is mediated through direct interaction with intestinal epithelial cells and modulation of the intraluminal environment.

EcN utilizes specific adhesins to bind to the intestinal mucosa, resulting in competitive exclusion against other microbial species for colonization sites. This binding and the subsequent secretion of specific outer membrane proteins initiate the modulation of gene expression within the enterocytes. The resulting intracellular cascade includes the enhanced synthesis of tight junction proteins and increased mucin production. This process reduces paracellular permeability, stabilizing the integrity of the epithelial barrier and restricting the passage of macromolecules into the lamina propria.

Furthermore, EcN is metabolically active, generating short-chain fatty acids (SCFAs) via the fermentation of non-digestible carbohydrates. These SCFAs serve as the primary energy source for colonocytes. The strain also produces microcins, which are bacteriocins that contribute to the inhibition of certain bacterial populations within the gut lumen.

Advertisements

Dosage and Administration Information

How Mutaflor is Used: Administration Guidelines

Mutaflor, which contains the live biotherapeutic Escherichia Coli strain Nissle 1917, is administered based on protocols focusing on the proper delivery and scheduling of the live culture.

Administration Scope

Instruction Domain Standard Guidelines
Route of Administration The primary route for both the enteric-coated capsules and the suspension is Oral. The suspension form may also be administered via gastric or intestinal tube.
Dosing Schedule Initial Phase (Capsules): Varies by region, such as 1 capsule daily for the first 4 days, or a higher dose of 2 capsules, 3 times daily, for the first 2 days. Maintenance Dose: Typically ranges from 2 to 4 capsules once daily.
Timing in relation to meals The dose should be taken with a meal, ideally with breakfast, and with an appropriate amount of fluid.

Administration Procedures and Patterns

The medicine's effectiveness relies on specific usage instructions that protect the bacterial strain:

  • Capsule Handling: The enteric-coated capsule must be swallowed whole without being crushed or chewed. This procedural rule is essential to ensure the capsule's coating remains intact and protects the bacterial strain from stomach acid, allowing for release in the lower digestive tract.
  • Dose Splitting: The total daily dose may be split and taken with meals throughout the day, particularly during the initial phase or if a higher maintenance dose is used.
  • Missed Dose: If administration is forgotten, the patient should not take a double dose; they should continue with the next scheduled dose as normal.
  • Duration of Use: The duration is based on the therapeutic scenario, ranging from a short course (e.g., up to 8 weeks) to periodic or continuous long-term maintenance regimens, as documented in prescribing information.
Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Mutaflor

The clinical evaluation of Mutaflor, which contains the specific bacterial strain Escherichia coli strain Nissle 1917 (EcN), has been primarily conducted through controlled clinical trials and systematic reviews. The available research was studied for specific digestive conditions, focusing on outcomes related to physical discomfort and the body's functional imbalance.


Evidence for Use in Ulcerative Colitis (UC)

The largest body of evidence for E. coli Nissle 1917 includes Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses involving adult patients with Ulcerative Colitis, a condition characterized by fluctuating or episodic manifestations. Research primarily studied the strain for the maintenance of remission (a phase where recurrence is monitored) over long-term periods, typically up to 12 months.

Studies explored how the strain compared to the standard drug mesalazine in participants with established remission. The research reported that measurements of relapse rates between the strain group and the mesalazine group were comparable.


Evidence for Chronic Constipation

Research explored the use of E. coli Nissle 1917 in adult populations with idiopathic chronic constipation through controlled clinical trials. These studies primarily focused on outcomes related to systemic or functional imbalance, measuring practical endpoints like the number of spontaneous bowel movements per week and changes in stool consistency. Reported outcomes were short-term and often based on single trials rather than a broad consensus across numerous large studies.


What Remains Uncertain in the Research

Research contributes to the broader evidence landscape, but it also highlights what is known—and what is still uncertain. Findings describe group patterns, not personal outcomes, and the evidence base contains several gaps and limitations.

  • Limited Long-Term Data: For many indications outside of UC, long-term effects are not fully established, and follow-up durations were limited.
  • Results Apply Only to the Populations Studied: There is limited information for groups such as children, older adults, and individuals with multiple severe conditions, as the primary research focused on defined adult cohorts.

Studies help show what has been observed so far, but the current body of research does not determine whether an individual will respond similarly, and research is ongoing.

Key Studies & References

  1. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis - Journal of Gastrointestinal and Liver Diseases
  2. Mutaflor Package Insert (Indications, Dosage, and Safety context from regulatory document)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Mutaflor (FAQ)


Q: Does Mutaflor need to be kept in the refrigerator?

A: Yes, Mutaflor must be stored in a refrigerator, at a temperature between 2, C and 8, C. This strict, low-temperature requirement is necessary to maintain the viability and effectiveness of the live bacterial culture, and the product must not be frozen.


Q: What are the most common reasons doctors prescribe Mutaflor?

A: Official regulatory documents define the specific conditions for which Mutaflor is indicated. These include the management of chronic constipation and, crucially, the maintenance of remission in patients with ulcerative colitis.


Q: Is Mutaflor safe for children?

A: Mutaflor is approved for use across various age groups, though the specific formulation is determined by age. The standard capsule form is approved for adolescents and adults, while the specific suspension form is listed in official documents for use in infants, toddlers, and younger children.


Q: Is Mutaflor suitable for people with a weakened immune system?

A: Official prescribing information advises caution when Mutaflor is used in immunocompromised individuals. This is a precaution detailed in regulatory documents.


Q: Are there any specific foods to avoid while taking Mutaflor?

A: Official regulatory documents do not list any specific food or alcohol products that must be avoided while taking Mutaflor. The medicine is generally recommended to be taken with a meal, often with breakfast.


Q: What's the difference between Mutaflor and common over-the-counter probiotics?

A: Mutaflor is officially classified as a medicine and a live biotherapeutic product. It contains a single, non-pathogenic bacterial strain (E. coli Nissle 1917) which is supported by clinical trials for specific medical indications.


Q: Does Mutaflor contain any dairy, gluten, or common allergens?

Because Mutaflor contains ingredients other than the active strain, the official documentation lists all excipients (inactive ingredients) in the product. Some formulations may contain ingredients such as lactose or components derived from sources like arachis oil (peanut oil). Individuals refer to the specific excipient list.


Q: What are the signs that Mutaflor is working for my condition?

A: Clinical studies measured specific endpoints to determine the efficacy of the medicine. For patients with chronic constipation, this involved tracking an increase in the number of complete spontaneous bowel movements per week. For ulcerative colitis, the key measure was the successful maintenance of remission.


Q: How quickly does Mutaflor usually start to work?

Studies examining Mutaflor's effects do not focus on immediate onset of action but rather on outcomes observed over a period of time. For example, clinical trials for chronic constipation typically measure changes in weekly bowel movements over an 8- to 12-week course. For chronic conditions like ulcerative colitis, the research primarily looks at long-term maintenance of remission over several months.


Q: How long can I expect to take Mutaflor?

A: The expected duration of administration is defined by the condition it is addressing. According to official product information, usage can range from a short course for some issues (such as up to eight weeks) to continuous or repeated periodic regimens for chronic conditions like maintaining remission in ulcerative colitis.


Q: Are there any known side effects for Mutaflor that aren't common?

A: Regulatory documents categorize adverse reactions based on their frequency. While common effects include flatulence (bloating), very rare effects, which may affect less than 1 in 10,000 people, may include abdominal pain, loose stools, diarrhea, nausea, vomiting, headaches, and skin reactions like rashes or reddening.


Q: Can Mutaflor be used during pregnancy?

A: Based on official prescribing information, there are no known risks during pregnancy or breastfeeding when Mutaflor is used as instructed. This is because the bacterium is considered a natural, non-absorbed gut inhabitant.


Q: Can Mutaflor be opened and mixed with liquid or food?

A: The capsule form of Mutaflor is designed with an enteric coating, which is essential to protect the live bacteria from stomach acid. Therefore, the capsule must be swallowed whole and should not be crushed or chewed. The suspension form, intended for infants and children, is administered as a liquid.


Q: What is the significance of the specific bacterial strain used in Mutaflor?

Mutaflor contains the non-pathogenic Escherichia coli strain Nissle 1917 (EcN), which is classified as a live biotherapeutic medicine. Official documents describe this specific strain as having unique properties, including competitive exclusion against certain microbes, strengthening the intestinal barrier function, and possessing immunomodulatory properties.


Q: Is there a maximum time Mutaflor is recommended to be used?

A: Official information states that Mutaflor may be used continuously for long periods or in repeated periodic regimens for chronic conditions. The duration is guided by the therapeutic scenario, and regulatory documents do not define a fixed maximum time limit for all types of use.


Q: Can Mutaflor cause changes in bowel habits?

A: Yes, as a gastrointestinal agent, the product is intended to modulate colonic motility and stabilize intestinal microflora, which can lead to changes in bowel habits. Furthermore, official documents list loose stools and diarrhea among the very rare side effects.


Q: Can people with lactose intolerance use Mutaflor?

A: The composition of the product, including excipients like lactose, is detailed in the official documents. Individuals may refer to the specific excipient list for their formulation, as some types of Mutaflor may contain lactose.


Q: What are the reported outcomes when Mutaflor is used for chronic constipation?

A: Studies reported positive outcomes when Mutaflor was used for chronic constipation, including an increase in the number of weekly bowel movements.


Q: Can Mutaflor be taken by people with a history of serious digestive disorders?

A: Mutaflor is specifically indicated for the maintenance of remission in ulcerative colitis, which is a chronic digestive disorder. However, official prescribing information notes that its use is conditional and should only occur during the established remission phase of the disease.


Q: Does Mutaflor contain any sugar or sweeteners?

A: The official excipient list details all components. Some formulations, particularly non-capsule forms, may contain sweeteners or sugars. For instance, some regulatory documents indicate that the mite capsule contains only a trace amount of usable carbohydrates per dose.


Q: What happens if Mutaflor is exposed to high temperatures?

A: Because Mutaflor contains a live bacterial culture, strict storage between 2, C and 8, C is required to protect the product’s viability. Exposure to temperatures outside this defined range risks reducing the number of viable bacteria, which may compromise the product's viability.


Q: Are there any age restrictions for taking Mutaflor?

A: Mutaflor is approved across all age groups, but the correct formulation must be used. The capsule form is approved for adolescents and adults, while the suspension is listed for use in infants, toddlers, and younger children.


Q: Why is Mutaflor sometimes preferred over other probiotic treatments?

A: Mutaflor is defined as a specific, non-pathogenic E. coli strain (Nissle 1917) and is positioned as a live biotherapeutic medicinal product. This status is supported by documented clinical evidence, notably in studies for ulcerative colitis.


Q: Is it possible for Mutaflor to make symptoms worse before they get better?

A: The most common reported side effect is flatulence (bloating), which is often observed at the very beginning of the administration period. Official documentation indicates that this initial symptom typically resolves with continued use of the medicine.


Q: Can Mutaflor be purchased without a doctor's consultation in some regions?

A: In some regions, Mutaflor is classified as an over-the-counter (OTC) medicine, meaning it may be purchased without a prescription. However, official product information in all jurisdictions suggests consultation with a doctor or healthcare practitioner prior to use.


Q: What's the difference between Mutaflor and Mutaflor mite?

A: The primary difference between Mutaflor and Mutaflor mite is the active substance strength. Mutaflor mite contains a lower count of the Escherichia coli Nissle 1917 bacterial strain compared to the standard Mutaflor capsule, and it is typically used for initial or reduced dosing.

Advertisements

How should Mutaflor be stored and disposed of?

How to Store and Dispose of Mutaflor?

Because Mutaflor contains a living bacterial culture, its storage requirements are strictly defined by regulatory documents to protect the product's viability.

Required Storage Conditions

Detail Requirement
Temperature Store in a refrigerator at a range of 2, C to 8, C.
Handling Do not freeze Mutaflor.
Packaging Keep the medicine in its original container or package.
Child Safety Must be kept out of the reach and sight of children.

Disposal

Unused or expired Mutaflor must be disposed of in accordance with local regulations. For the suspension form, official labeling states there are no special requirements for disposal. The product must not be used after the expiry date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mutaflor found in:

A-Z Index: